HC Deb 12 March 2003 vol 401 c337W
Tim Loughton

To ask the Secretary of State for Health what restenosis rate was associated with the use of bare stents in diabetics in the last year for which figures are available. [102143]

Ms Blears

No information is held on restenosis levels among patients suffering from diabetes.

Tim Loughton

To ask the Secretary of State for Health what assessment he has made of how many diabetics with heart disease would benefit from the use of drug eluting stents in percutaneous coronary intervention. [102144]

Ms Blears

The current evaluation by the National Institute for Clinical Excellence of the clinical and cost effectiveness of drug eluting stents will consider, inter alia, the implications of patient co-morbidity. Publication of the evaluation's results is expected during August 2003.

Tim Loughton

To ask the Secretary of State for Health if he will provide guidance to primary care trusts on the use of drug eluting stents in patients who are at high risk of having restenosis. [102145]

Ms Blears

Guidance to clinicians is currently in preparation by the National Institute for Clinical Excellence on the clinical effectiveness of drug eluting stents. Publication of this guidance is scheduled for August 2003. Pending publication, the national health service has standing guidance to take decisions locally on the best available evidence as to whether, and in what circumstances, to fund and deploy any particular intervention.

Back to